Status:
COMPLETED
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Pain
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.
Eligibility Criteria
Inclusion
- Healthy Caucasians, males or females aged ≥20 and ≤ 45 years or between 65 80 years. Female subjects must be surgically sterile or post-menopausal for at least 12 months prior to the enrolment visit.
- Body Mass Index (BMI) of ≥18 to ≤ 30 kg/m2 and weight of ≥50 to ≤100 kg
- Clinically normal physical findings including heart rate \> 45 bpm and laboratory values and normal resting ECG
Exclusion
- History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study.
- History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity.
- Subjects with a high decrease in blood pressure within 5 minutes when going from a supine to standing position.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00690079
Start Date
February 1 2008
End Date
October 1 2008
Last Update
December 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Macclesfield, Cheshire, United Kingdom